37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups

Authors:
  • MPM.A. Powell
    M.A. Powell
  • AAA. Auranen
    A. Auranen
  • LWL.J. Willmott
    L.J. Willmott
  • LGL. Gilbert
    L. Gilbert
  • DBD. Black
    D. Black
  • DCD. Cibula
    D. Cibula
  • SSS. Sharma
    S. Sharma
  • GVG. Valabrega
    G. Valabrega
  • LLL.M. Landrum
    L.M. Landrum
  • LHL.C. Hanker
    L.C. Hanker
  • ASA. Stuckey
    A. Stuckey
  • IBI.A. Boere
    I.A. Boere

Abstract
No abstract available
Funding Information
  • GlaxoSmithKline